The FDA approved bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal antibody, in combination with chemotherapy for frontline and maintenance therapy for women with newly diagnosed ovarian cancer. This evidence concerns the gene VEGFA and ovarian carcinoma.